DDInter1139 DDInter1387
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Niflumic Acid
Niflumic Acid {u} (Compound) resembles {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may lead to a major life threatening interaction when taken with Panobinostat
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Panobinostat
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Flurbiprofen may lead to a major life threatening interaction when taken with Panobinostat
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Mefenamic acid (Compound) resembles Niflumic Acid (Compound) and Niflumic Acid (Compound) resembles Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Panobinostat
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat